Drug Trial Radar · NCT00856583
Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use
Last checked: Nov 19, 2026Latest source record: Aug 19, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,809
Actual
Start
Jul 2002
Primary completion
Feb 2008
Study completion Feb 2008
Sponsor
- Lead sponsor
- H. Lundbeck A/SIndustry
- Sponsor type
- Industry
- First posted
- Mar 6, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine whether there is an increased all-cause mortality in sertindole-treated patients in comparison to patients treated with a well-known antipsychotic (risperidone) when used under normal marketed conditions in the treatment of schizophrenia.
Conditions
- Schizophrenia
Interventions
SertindoleDrug
Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
RisperidoneDrug
Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With All-cause MortalityTime frame: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
- Second Primary Outcome: Number of Participants With Cardiac Events, Including Arrhythmias, Requiring HospitalisationTime frame: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.